# Clinical Study of Recombinant Anti-CD19m-CD3 Antibody Injection (A-319)

> **NCT07371533** · NA · NOT_YET_RECRUITING · sponsor: **Shanxi Bethune Hospital** · enrollment: 18 (estimated)

## Conditions studied

- Acute Lymphocytic Leukemia

## Interventions

- **DRUG:** Treatment with A319

## Key facts

- **NCT ID:** NCT07371533
- **Lead sponsor:** Shanxi Bethune Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-02
- **Primary completion:** 2027-09-30
- **Final completion:** 2028-01-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07371533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07371533, "Clinical Study of Recombinant Anti-CD19m-CD3 Antibody Injection (A-319)". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT07371533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*